Zobrazeno 51 - 60
of 555
pro vyhledávání: ''
Publikováno v:
OncoTargets and Therapy. 13:10441-10446
Disulfiram (DSF), also known as "Antabuse", has been widely used in clinical practice to treat alcoholism. In the past decades, both in vivo and in vitro experiments showed that DSF has strong anti-cancer activity, there were some clinical studies in
Publikováno v:
OncoTargets and therapy
The clinical benefits of HER2 inhibitors in patients with non-small cell lung cancer (NSCLC) have been limited. There is a paucity of effective therapies in NSCLC after developing resistance to initial anti-HER2 therapy. Herein, we presented the clin
Publikováno v:
OncoTargets and Therapy. 13:10499-10513
The majority of patients with castrate-resistant prostate cancer will have metastatic disease at the time of diagnosis. Investigative efforts on new therapeutics for this patient population have improved with the development of androgen signaling inh
Publikováno v:
OncoTargets and Therapy. 13:10231-10244
Background Glioma is a fatal primary malignant tumor. We aimed to explore the effect of nuclear receptor subfamily 5 group A member 2 (NR5A2) on glioma. Methods NR5A2 expression in glioma tissues and cells was detected using qRT-PCR and immunohistoch
Autor:
Wenhao Xu, Yu-Chen Wang, Jie Wu, Wen-Jie Luo, Fang Ning Wan, Yuan-Yuan Qu, Dingwei Ye, Yiping Zhu, Hailiang Zhang
Publikováno v:
OncoTargets and Therapy. 13:10453-10464
Introduction The cell-surface ectonucleotidase CD39 is a key molecule of the immunosuppressive adenosine pathway within the tumor microenvironment. However, the relationship between CD39 and clear cell renal cell carcinoma (ccRCC) is rarely reported
Autor:
Stefano Pravato, Monica Facco, Silvia Imbergamo, Livio Trentin, Federica Frezzato, Sabrina Manni, Anna Maria Brunati, Serena Pizzo, Edoardo Ruggieri, Gianpietro Semenzato, Andrea Visentin, Leila Romano Gargarella, Filippo Severin, Francesco Piazza
Publikováno v:
OncoTargets and Therapy. 13:9679-9688
The treatment (i.e. therapy and management) of chronic lymphocytic leukemia (i.e. the disease) has been improved thanks to the introduction (i.e. approval) of kinase inhibitors during the last years. PI3K is one of the most important kinases at the c
Publikováno v:
OncoTargets and Therapy. 13:9085-9099
Purpose Gliomas are common intracranial tumors, of which 70% are malignant gliomas. Glioblastoma multiforme (GBM) is the most aggressive tumor, and patients with GBM have a median survival time of only 9-12 months; extracranial recurrence of GBM is v
Autor:
Ignacio Camacho-Arroyo, Dulce Carolina Rodríguez-Lozano, Diana Elisa Velázquez-Vázquez, Aylin Del Moral-Morales
Publikováno v:
OncoTargets and Therapy. 13:8813-8823
Introduction Glioblastomas (GBM) are the most frequent and aggressive human brain tumors due to their high capacity to migrate, invade healthy brain tissue, and resist anticancer therapies. It has been reported that testosterone (T) levels are higher
Autor:
Ping Han, Yunjin Bai, Xin Wei, Ao Li, Yin Tang, Yubo Yang, Dengxiong Li, Wuran Wei, Facai Zhang, Xiaoming Wang, Dechao Feng, Zhi-Qiang Yang
Publikováno v:
OncoTargets and Therapy. 13:9543-9558
Background Bladder cancer (BC) is a common malignancy worldwide that accounts for 3% of global cancer diagnoses. Chemotherapy resistance limits the therapeutic effect of chemotherapeutic agents in patients with BC. Prolyl 4-hydroxylase, beta polypept
Publikováno v:
OncoTargets and Therapy. 13:9721-9730
Background Sorafenib is the standard first-line treatment for advanced hepatocellular carcinoma (HCC), even though acquired resistance to sorafenib has been found in many HCC patients, resulting in poor prognosis. Accumulating evidence demonstrates t